Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
January-2018 Volume 17 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2018 Volume 17 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells

  • Authors:
    • Jing Wang
    • Hui‑Min Gong
    • Hui‑Hui Zou
    • Ling Liang
    • Xin‑Yi Wu
  • View Affiliations / Copyright

    Affiliations: Department of Ophthalmology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Ophthalmic Center, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China, Department of Ophthalmology, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China
  • Pages: 648-652
    |
    Published online on: October 27, 2017
       https://doi.org/10.3892/mmr.2017.7916
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Isorhamnetin, a 3‑O‑methylated metabolite of quercetin, exhibits antioxidant effects. However, to the best of our knowledge, no study to date has focused on the effects of isorhamnetin on retinal pigment epithelium (RPE) cells, and its underlying molecular mechanisms. Therefore, the present study aimed to examine the potential protective effect of isorhamnetin against oxidative stress in human RPE cells. The results demonstrated that pretreatment of RPE cells with isorhamnetin significantly protected cell viability against oxidative stress. In addition, isorhamnetin pretreatment inhibited hydrogen peroxide (H2O2)‑induced reactive oxygen species (ROS) production and caspase‑3 activation in RPE cells. Furthermore, isorhamnetin pretreatment significantly increased the phosphorylation of phosphoinositide 3‑kinase (PI3K) and AKT serine/threonine kinase 1 (Akt) in RPE cells exposed to H2O2, compared with cells treated with H2O2 alone. Taken together, the present results demonstrated that isorhamnetin protected human RPE cells from oxidative stress‑induced cell death, and this effect was associated with activation of the PI3K/Akt signaling pathway. Thus, isorhamnetin may be considered as a potential antioxidant useful for the prevention of age‑related macular degeneration.

Introduction

Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly in developed countries (1). Epidemiological studies have demonstrated that the prevalence of AMD in the aged population is increasing steadily every year (2). The retinal pigment epithelium (RPE), which forms a blood-retinal barrier between the neural retina and choriocapillaris, serves a pathophysiological role in the process of AMD (3). Oxidative stress is crucial in the development of AMD (4,5). Previous studies have reported that RPE cells are susceptible to oxidative damage, and oxidative stress from hydrogen peroxide (H2O2) leads to RPE cell death by causing preferential damage to mitochondrial DNA (6,7). Thus, strategies for protecting RPE cells against oxidative damage may be helpful for preventing the progression of AMD.

Isorhamnetin is one of the major active components isolated from herbal medicinal plants, such as Hippophae rhamnoides and Ginkgo biloba (8). Previous studies have indicated that isorhamnetin exhibits anti-inflammatory and antitumor effects, and that it protects ventricular myocytes from ischemia and reperfusion injury (9–11). In addition, isorhamnetin has been reported to exhibit antioxidant properties (12–14). Choi (15) reported that isorhamnetin reverses H2O2-induced growth inhibition and exhibits scavenging activity against intracellular reactive oxygen species (ROS) in mouse-derived C2C12 myoblasts (15). However, the effects of isorhamnetin on RPE cells and the underlying molecular mechanism remain unclear. Therefore, the aim of the present study was to examine the effect of isorhamnetin against oxidative stress in human RPE cells.

Materials and methods

Reagents and antibodies

Isorhamnetin (purity >98 %) was purchased from Shanghai Tongtian Biotechnology Co., Ltd. (Shanghai, China). Antibodies against phosphoinositide 3-kinase (PI3K; 1:2,000; cat no. sc-365290), phosphorylated (p)-PI3K (1:2,000; cat no. sc-293115), AKT serine/threonine kinase 1 (Akt; 1:2,000; cat no. sc-5298), p-Akt (1:2,000; cat no. sc-52940), GAPDH (1:1,000; cat no. sc-365062) and horseradish peroxidase-conjugated secondary antibodies (1;3,000; cat no. sc-2370) were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). All other chemicals and reagents were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Cell culture

The human RPE cell line ARPE-19 was purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM/Nutrient Mixture F-12 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (Sigma-Aldrich; Merck KGaA) and 1% penicillin/streptomycin, in a 37°C incubator under a humidified atmosphere containing 5% CO2.

Cell viability assay

Cell viability was evaluated using an MTT assay. Briefly, ARPE-19 cells (4×104 cells/well) were pretreated with various concentrations of isorhamnetin (25, 50 and 100 µM) for 24 h prior to exposure to 250 µM H2O2 for 24 h. The medium was then replaced with fresh medium containing 0.5 mg/ml MTT for 4 h at 37°C. The MTT formazan crystals were dissolved in dimethyl sulfoxide, and the absorbance was measured at 450 nm with a microplate reader (Omega Bio-Tek, Inc., Norcross, GA, USA). The relative cell viability was defined as the absorbance of treated cells divided by that of the control untreated cells.

Measurement of intracellular ROS generation

Intracellular ROS production was measured using the 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) probe (Sigma-Aldrich; Merck KGaA). Briefly, following treatment, ARPE-19 cells were washed twice with PBS, and then incubated with 10 mM H2DCFDA for 30 min at 37°C in the dark. Then, the cells were harvested and fluorescence of the resulting dichlorofluorescein (DCF) was measured using an F-2500 spectrophotometer (Hitachi, Ltd., Tokyo, Japan) at 488 nm excitation and 525 nm emission. The results were expressed as the fluorescence intensity of DCF of each sample relative to the control.

Caspase-3 activity assay

Caspase-3 activity was detected using a caspase-3 cellular activity assay kit (Merck KGaA), as per the manufacturer's instructions. Briefly, following treatment, ARPE-19 cells were harvested and then suspended in the cell lysis buffer. Cell lysates were incubated in the presence or absence of 5 µl Asp-Glu-Val-Asp-p-nitroanilide at 37°C for 1 h. Following washing, the fluorescence released by active caspase-3 was measured using a microplate reader at 405 nm wavelength.

Western blot analysis

ARPE-19 cells were harvested, washed twice with PBS, and lysed in radioimmunoprecipitation assay buffer containing 1 mM phenylmethylsulfonyl fluoride (both from Shenneng Bocai Biotechnology Co., Ltd., Shanghai, China) on ice for 10 min. Cell lysates were centrifuged at 13,000 × g for 15 min at 4°C. The supernatants were collected, and the protein content of each lysate was measured by BCA protein assay (Pierce; Thermo Fisher Scientific, Inc.). Protein (30 µg/lane) was separated by electrophoresis on a 10% SDS-polyacrylamide gel and transferred electrophoretically to a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked in 5% non-fat dry milk and TBST buffer (5 mM Tris-HCl, pH 7.4, 136 mM NaCl and 0.1% Tween-20) for 1 h at room temperature, and incubated with specific antibodies (p-PI3K, PI3K, p-Akt, Akt, and GAPDH) overnight at 4°C. Then, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.) for another 1 h at room temperature. The blots were visualized with an enhanced chemiluminescence system (GE Healthcare Life Sciences, Chalfont, UK) and grey intensity analysis was performed using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

Statistical analysis

The SPSS software package (version 17.0; SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are expressed as mean ± standard deviation of three independent experiments performed in triplicate. Significant differences were determined using a Student's t-test or one-way analysis of variance followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Isorhamnetin is not cytotoxic in ARPE-19 cells

First, the potential cytotoxicity of isorhamnetin was examined on human ARPE-19 cells using the MTT assay. As demonstrated in Fig. 1, isorhamnetin did not significantly affect the viability of ARPE-19 cells in doses up to 100 µM. Therefore, 25–100 µM of isorhamnetin was used for treatments in the following experiments.

Figure 1.

Effect of isorhamnetin treatment on ARPE-19 cell viability. ARPE-19 cells were pretreated with various concentrations of isorhamnetin (0, 25, 50 and 100 µM) for 24 h, and cell viability was determined by MTT assay. Data are expressed as mean ± standard deviation of three independent experiments.

Isorhamnetin treatment protects human RPE cells against oxidative stress

The effect of isorhamnetin on the cell viability of H2O2-treated ARPE-19 cells was examined by MTT assay. The results demonstrated that H2O2 treatment resulted in a significant decrease in cell viability compared with untreated cells, whereas pretreatment with isorhamnetin significantly reversed this decrease in a dose-dependent manner (Fig. 2).

Figure 2.

Isorhamnetin treatment protects human retinal pigment epithelium cells against oxidative stress. ARPE-19 cells were pretreated with various concentrations of isorhamnetin (0, 25, 50 and 100 µM) for 24 h, prior to exposure to 250 µM H2O2 for 24 h. Cell viability was determined by MTT assay. Data are expressed as mean ± standard deviation of three independent experiments. *P<0.05 vs. control untreated group; #P<0.05 vs. H2O2 group. H2O2, hydrogen peroxide.

Isorhamnetin treatment inhibits H2O2-induced ROS production in human RPE cells

Increased ROS levels result in oxidative stress and are hypothesized to be critical in the pathogenesis of AMD. Therefore, the effect of isorhamnetin on ROS generation was examined in ARPE-19 cells exposed to H2O2. As indicated in Fig. 3, treatment with H2O2 for 24 h dramatically increased the production of ROS compared with control untreated cells. However, pretreatment with isorhamnetin significantly suppressed the H2O2-induced ROS production in a dose-dependent manner (Fig. 3).

Figure 3.

Isorhamnetin treatment inhibits H2O2-induced ROS production in human retinal pigment epithelium cells. ARPE-19 cells were pretreated with various concentrations of isorhamnetin (0, 25, 50 and 100 µM) for 24 h prior to exposure to 250 µM H2O2 for 24 h. Intracellular ROS production was measured using a 2′,7′-dichlorodihydrofluorescein diacetate probe. Data are expressed as mean ± standard deviation of three independent experiments. *P<0.05 vs. control untreated group; #P<0.05 vs. H2O2 group. H2O2, hydrogen peroxide.

Isorhamnetin treatment inhibits H2O2-induced caspase-3 activity in human RPE cells

Caspase-3 is a main executor and an established marker of cell apoptosis, so caspase-3 activity was measured as a surrogate for cell death initiation (16). As demonstrated in Fig. 4, H2O2 treatment significantly increased caspase-3 activity, compared with untreated control. This H2O2-induced increase in caspase-3 activity, however, was dramatically attenuated by isorhamnetin pretreatment in a dose-dependent manner (Fig. 4).

Figure 4.

Isorhamnetin treatment inhibits H2O2-induced caspase-3 activation in retinal pigment epithelium cells. ARPE-19 cells were pretreated with various concentrations of isorhamnetin (0, 25, 50 and 100 µM) for 24 h prior to exposure to 250 µM H2O2 for 24 h. Caspase-3 activity was measured using a caspase-3 cellular activity assay kit. Data are expressed as mean ± standard deviation of three independent experiments. *P<0.05 vs. control untreated group; #P<0.05 vs. H2O2 group. H2O2, hydrogen peroxide.

Isorhamnetin treatment activates the PI3K/Akt pathway in human RPE cells

Activation of the PI3K/Akt signaling pathway is important in protecting RPE cells from oxidative stress (17). Therefore, the hypothesis that the PI3K/Akt pathway may be involved in the protective effects of isorhamnetin on H2O2-induced cell death was tested in ARPE-19 cells. As demonstrated in Fig. 5, phosphorylation of PI3K and Akt were significantly decreased by H2O2 treatment, compared with the control group, as evident by the decreased p-PI3K/PI3K and p-Akt/Akt ratios. However, pretreatment with isorhamnetin for 24 h markedly increased phosphorylation of both PI3K and Akt in ARPE-19 cells exposed to H2O2, compared with cells treated with H2O2 alone (Fig. 5).

Figure 5.

Isorhamnetin treatment results in PI3K/Akt pathway activation in retinal pigment epithelium cells. ARPE-19 cells were pretreated with various concentrations of isorhamnetin (0, 25, 50 and 100 µM) for 24 h prior to exposure to 250 µM H2O2 for 24 h. Protein expression levels of p-PI3K, total PI3K, p-Akt, total Akt and GAPDH (as a loading control) were examined by western blotting. (A) Representative images. (B) Quantitative analysis of p-PI3K/PI3K ratio. (C) Quantitative analysis of p-Akt/Akt ratio. Data are expressed as mean ± standard deviation of three independent experiments. *P<0.05 vs. control untreated group; #P<0.05 vs. H2O2 group. PI3K, phosphoinositide 3-kinase; Akt, AKT serine/threonine kinase 1; H2O2, hydrogen peroxide; p, phosphorylated.

Discussion

The present study focused on the effect of isorhamnetin on oxidative stress in human RPE cells. The results provide the first evidence that pretreatment of RPE cells with isorhamnetin significantly protected cell viability against oxidative stress. Furthermore, isorhamnetin inhibited H2O2-induced ROS production and caspase-3 activation in ARPE-19 cells. This protective effect of isorhamnetin may be mediated through PI3K/Akt signaling in ARPE-19 cells.

H2O2 is a well-established model of oxidative stress in RPE cells because of its rapid membrane permeability (18). A vast array of studies have demonstrated that oxidative stress induced by chemical oxidants, such as H2O2, leads to RPE damage and cell death (5,19,20). For these reasons, H2O2 was selected in the present study as an inducer of oxidative stress in human RPE cells to investigate the effect of isorhamnetin. The results demonstrated that H2O2 treatment resulted in a significant decrease in viability of ARPE-19 cells. However, pretreatment with isorhamnetin significantly reversed this decrease in a dose-dependent manner, implying that isorhamnetin exhibits a protective effect against oxidative stress in RPE cells.

Oxidative damage is important in the pathogenesis of AMD. ROS levels are increased in retinas of patients with AMD, resulting in oxidization of key cellular components in local RPE cells and severe RPE damage (21). It has been reported that isorhamnetin pretreatment blocks tertiary-butyl hydroperoxide-induced ROS production in hepatocytes (12). Sun et al (22) reported that isorhamnetin significantly decreases ROS generation in H9c2 cardiomyocytes exposed to H2O2. In accordance with these previous reports, the present results demonstrated that H2O2 treatment significantly increased intracellular ROS production in human RPE cells compared with untreated cells, and that this effect was significantly inhibited by isorhamnetin pretreatment. These results suggest that isorhamnetin protected ARPE-19 cells from H2O2-induced cell damage through its antioxidant activity.

Caspase-3 activation is an initiative process of cell apoptosis (23). It has been reported that exposure of RPE cells to increased ROS results in mitochondrial DNA damage and induces caspase-3 activation (24). In the present study, pretreatment with isorhamnetin was demonstrated to significantly suppress H2O2-induced caspase-3 activation, compared with cells treated with H2O2 alone. These data suggest that isorhamnetin protected ARPE-19 cells from H2O2-induced cell damage via its anti-apoptotic effect.

There is substantial evidence that the PI3K/Akt signaling pathway is involved in regulating the antioxidant function in RPE cells (25–27). Akt becomes phosphorylated in a PI3K-dependent manner in response to oxidants, such as H2O2, in human RPE cells, and treatment with a PI3K inhibitor (LY294002) blocks H2O2-mediated Akt phosphorylation and significantly enhances caspase-associated RPE cell death (28); this result is different to that observed in the present study which, may be due to the length of H2O2 exposure. In the study by Yang et al (28), when RPE cells were exposed to H2O2 for 15 min, p-Akt levels increased. However, in the present study, cells were exposed to H2O2 for 24 h, and the phosphorylation of PI3K and Akt significantly decreased. A recent study reported that isorhamnetin attenuates atherosclerosis by suppressing apoptosis in THP-1-derived macrophages via PI3K/Akt activation (29). In the present study, it was demonstrated that pretreatment with isorhamnetin significantly enhanced phosphorylation of PI3K and Akt in RPE cells exposed to H2O2, compared to cells exposed to H2O2 alone. These data suggest that isorhamnetin may have protected human RPE cells from oxidative stress-induced cell death, through activation of the PI3K/Akt signaling pathway.

In summary, the present report demonstrated that isorhamnetin protected human RPE cells from oxidative stress-induced cell death, which may be associated with the activation of PI3K/Akt signaling. Thus, isorhamnetin may be considered as a potential antioxidant agent towards the prevention of AMD.

References

1 

Congdon NG, Friedman DS and Lietman T: Important causes of visual impairment in the world today. JAMA. 290:2057–2060. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Fletcher EC and Scholl HP: Ophthalmic disease in the ageing society. Ophthalmology and the Ageing Society. 1–9. 2013. View Article : Google Scholar

3 

Curcio CA, Zanzottera EC, Messinger JD, Ach T, Smith T and Freund KB: Retinal pigment epithelium (RPE) transdifferentiation and death in age-related macular degeneration (AMD), seen in the Project MACULA grading system. Invest Ophth Vis Sci. 56:893. 2015.

4 

Beatty S, Koh HH, Phil M, Henson D and Boulton M: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 45:115–134. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Jarrett SG and Boulton ME: Consequences of oxidative stress in age-related macular degeneration. Mol Aspects Med. 33:399–417. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Liang FQ and Godley BF: Oxidative stress-induced mitochondrial DNA damage in human retinal pigment epithelial cells: A possible mechanism for RPE aging and age-related macular degeneration. Exp Eye Res. 76:397–403. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Drobek-Słowik M, Karczewicz D and Safranow K: The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD). Postepy Hig Med Dosw (Online). 61:28–37. 2007.(In Polish). PubMed/NCBI

8 

Park JC, Young HS, Yu YB and Lee JH: Isorhamnetin sulphate from the leaves and stems of oenanthe javanica in korea. Planta Med. 61:377–378. 1995. View Article : Google Scholar : PubMed/NCBI

9 

Chen TL, Zhu GL, Wang JA, Zhang GD, Liu HF, Chen JR, Wang Y and He XL: Protective effects of isorhamnetin on apoptosis and inflammation in TNF-α-induced HUVECs injury. Int J Clin Exp Pathol. 8:2311–2320. 2015.PubMed/NCBI

10 

Saud SM, Young MR, Jones-Hall YL, Ileva L, Evbuomwan MO, Wise J, Colburn NH, Kim YS and Bobe G: Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β-catenin. Cancer Res. 73:5473–5484. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Zhang N, Pei F, Wei H, Zhang T and Yang C, Ma G and Yang C: Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury. Exp Toxicol Pathol. 63:33–38. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Yang JH, Shin BY, Han JY, Kim MG, Wi JE, Kim YW, Cho IJ, Kim SC, Shin SM and Ki SH: Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Applied Pharmacol. 274:293–301. 2014. View Article : Google Scholar

13 

Kong CS, Kim JA, Qian ZJ, Kim YA, Lee JI, Kim SK, Nam TJ and Seo Y: Protective effect of isorhamnetin 3-О-β-d-glucopyranoside from Salicornia herbacea against oxidation-induced cell damage. Food Chem Toxicol. 47:1914–1920. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Bouhlel I, Skandrani I, Nefatti A, Valenti K, Ghedira K, Mariotte AM, Hininger-Favier I, Laporte F, Dijoux-Franca MG and Chekir-Ghedira L: Antigenotoxic and antioxidant activities of isorhamnetin 3-O neohesperidoside from Acacia salicina. Drug Chem Toxicol. 32:258–267. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Choi YH: The cytoprotective effect of isorhamnetin against oxidative stress is mediated by the upregulation of the Nrf2-dependent HO-1 expression in C2C12 myoblasts through scavenging reactive oxygen species and ERK inactivation. Gen Physiol Biophs. 35:145–154. 2016. View Article : Google Scholar

16 

Jänicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:9357–9360. 1998. View Article : Google Scholar : PubMed/NCBI

17 

Faghiri Z and Bazan NG: PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotection D1-induced retianl pigment epithelial cell survival during oxidarive stress-induced apoptosis. Exp Eye Res. 90:718–725. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Kim MH, Chung J, Yang JW, Chung SM, Kwag NH and Yoo JS: Hydrogen peroxide-induced cell death in a human retinal pigment epithelial cell line, ARPE-19. Korean J Ophthalmol. 17:19–28. 2003. View Article : Google Scholar : PubMed/NCBI

19 

Hanneken A, Lin FF, Johnson J and Maher P: Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 47:3164–3177. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Sreekumar PG, Kannan R, Yaung J, Spee CK, Ryan SJ and Hinton DR: Protection from oxidative stress by methionine sulfoxide reductases in RPE cells. Biochem Bioph Res Co. 334:245–253. 2005. View Article : Google Scholar

21 

Cai J, Nelson KC, Wu M, Sternberg P Jr and Jones DP: Oxidative damage and protection of the RPE. Prog Retin Eye Res. 19:205–221. 2000. View Article : Google Scholar : PubMed/NCBI

22 

Sun B, Sun GB, Xiao J, Chen RC, Wang X, Wu Y, Cao L, Yang ZH and Sun XB: Isorhamnetin inhibits H2O2-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation. J Cell Biochem. 113:473–485. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI

24 

Kook D, Wolf AH, Alice LY, Neubauer AS, Priglinger SG, Kampik A and Welge-Luüssen UC: The protective effect of quercetin against oxidative stress in the human RPE in vitro. Invest Ophth Vis Sci. 49:1712–1720. 2008. View Article : Google Scholar

25 

Wang R, Peng L, Zhao J, Zhang L, Guo C, Zheng W and Chen H: Gardenamide A protects RGC-5 cells from H2O2-induced oxidative stress insults by activating PI3K/Akt/eNOS signaling pathway. Int J Mol Sci. 16:22350–22367. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Zha X, Wu G, Zhao X, Zhou L, Zhang H, Li J, Ma L and Zhang Y: PRDX6 protects ARPE-19 cells from oxidative damage via PI3K/AKT signaling. Cell Physiol Biochem. 36:2217–2228. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Li Z, Dong X, Liu H, Chen X, Shi H, Fan Y, Hou D and Zhang X: Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt. Mol Vis. 19:1656–1666. 2013.PubMed/NCBI

28 

Yang P, Peairs JJ, Tano R and Jaffe GJ: Oxidant-mediated Akt activation in human RPE cells. Invest Ophthalmol Vis Sci. 47:4598–4606. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Luo Y, Sun G, Dong X, Wang M, Qin M, Yu Y and Sun X: Isorhamnetin attenuates atherosclerosis by inhibiting macrophage apoptosis via PI3K/AKT activation and HO-1 induction. PLoS One. 10:e01202592015. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wang J, Gong HM, Zou HH, Liang L and Wu XY: Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells. Mol Med Rep 17: 648-652, 2018.
APA
Wang, J., Gong, H., Zou, H., Liang, L., & Wu, X. (2018). Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells. Molecular Medicine Reports, 17, 648-652. https://doi.org/10.3892/mmr.2017.7916
MLA
Wang, J., Gong, H., Zou, H., Liang, L., Wu, X."Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells". Molecular Medicine Reports 17.1 (2018): 648-652.
Chicago
Wang, J., Gong, H., Zou, H., Liang, L., Wu, X."Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells". Molecular Medicine Reports 17, no. 1 (2018): 648-652. https://doi.org/10.3892/mmr.2017.7916
Copy and paste a formatted citation
x
Spandidos Publications style
Wang J, Gong HM, Zou HH, Liang L and Wu XY: Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells. Mol Med Rep 17: 648-652, 2018.
APA
Wang, J., Gong, H., Zou, H., Liang, L., & Wu, X. (2018). Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells. Molecular Medicine Reports, 17, 648-652. https://doi.org/10.3892/mmr.2017.7916
MLA
Wang, J., Gong, H., Zou, H., Liang, L., Wu, X."Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells". Molecular Medicine Reports 17.1 (2018): 648-652.
Chicago
Wang, J., Gong, H., Zou, H., Liang, L., Wu, X."Isorhamnetin prevents H2O2‑induced oxidative stress in human retinal pigment epithelial cells". Molecular Medicine Reports 17, no. 1 (2018): 648-652. https://doi.org/10.3892/mmr.2017.7916
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team